Komfoderm K, cream 0.1% 15 g

Inflammatory skin diseases susceptible to therapy with topical glucocorticosteroids: atopic dermatitis, neurodermatitis, pediatric eczema; true eczema; microbial eczema; simple contact dermatitis; allergic (contact) dermatitis; dyshydrotic eczema.

Indications

Inflammatory skin diseases sensitive to therapy with topical glucocorticosteroids: atopic dermatitis, neurodermatitis, childhood eczema; true eczema; microbial eczema; simple contact dermatitis; allergic (contact) dermatitis; dyshidrotic eczema.

Pharmacological effect

Glucocorticosteroid for local use

Special instructions

For bacterial dermatoses/dermatomycosis, in addition to Comfoderm K, specific antibacterial or antimycotic treatment is required.

The cream is not intended for use in ophthalmology.

It is necessary to avoid contact with mucous membranes and eyes.

After external use of Comfoderm K, the development of glaucoma is possible (for example, during therapy with large doses, due to application to the skin around the eyes or very long-term use of occlusive dressings).

Active ingredient

Methylprednisolone aceponate

Composition

Composition of 100 mg cream:

active substance:

Methylprednisolone aceponate – 0.1 mg (calculated as 100% substance);

auxiliary components:

macrogol stearate 40 – 1.5 mg;
glyceryl monostearate – 8.5 mg;
potassium dihydrogen phosphate – 0.49 mg;
ceramides – 0.5 mg;
preservative Euxyl PE 9010 (ethylhexylglycerol – 10%, phenoxyethanol – 90%) – 0.9 mg (in terms of phenoxyethanol);
sodium hydrogen phosphate dodecahydrate – 0.01 mg;
isopropyl myristate – 7 mg;
edetate disodium – 0.1 mg;
octyldodecanol – 7 mg;
hexyldecyl stearate – 7 mg;
dimethicone 100 cst – 1 mg;
cetostearyl alcohol (stearyl alcohol – 40%, cetyl alcohol – 60%) – 2 mg;
propylene glycol – 7 mg;
purified water – up to 100 mg.

Contraindications

Hypersensitivity to the components of the drug; tuberculous or syphilitic processes in the area of ​​application of the drug; viral diseases (for example, chickenpox, herpes zoster) in the area of ​​application of the drug; rosacea, perioral dermatitis in the area of ​​application of the drug; areas of skin with manifestations of a reaction to vaccination; children up to 4 months of age.

Side Effects

The incidence of side effects is classified according to the recommendations of the World Health Organization (WHO): very common (≥ 10%), common (≥ 1%, < 10%), uncommon (≥ 0.1%, < 1%), rare (≥ 0.01%, < 0.1%), very rare (< 0.01%), frequency unknown (it is not possible to estimate the frequency of occurrence).Disorders of the skin and subcutaneous tissues: rarely, perioral dermatitis, skin depigmentation, allergic reactions to the components of the drug; frequency unknown: skin atrophy, telangiectasia, striae, acne-like skin changes (when using the drug for more than 4 weeks and/or on an area of ​​10% or more of the body surface).General disorders and disorders at the injection site: rarely – folliculitis, hypertrichosis; very rarely – itching, burning, erythema, formation of a vesicular rash; frequency unknown – systemic effects caused by glucocorticosteroid absorption (when using the drug for more than 4 weeks and/or on an area of ​​10% or more of the body surface).If any of the side effects indicated in the instructions worsen, or any other side effects not listed in the instructions are noted, you should immediately inform your doctor.

Interaction

There are no data on the interaction of Comfoderm K with other drugs/substances.

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of the reach of children.

Manufacturer

Akrikhin JSC, Russia